The novel therapeutic cancer peptide vaccine therapy for patients with locally advanced or metastatic pacreatic cancer combined with Gemcitabine as the first line therapy.-Phase I/II study
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000014481
- Lead Sponsor
- Second Department of Surgery, Wakayama Medical University, School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Not provided
1)History of other active malignancy 2)Pancreatic cancer infiltrated into digestive tract with serious concern of bleeding 3)Interstitial pneumonia or pulmonary fibrosis 4)Brain metastasis or symptoms of it 5)Pleural effusion, ascites, and pericardial fluid requiring drainage 6)Active infections 7)Severe nervous disorder or mental disorder 8)Severe organ disorder, equivalent to CTCAE grade3 or greater 9)History of ischemic heart disease, cerebral infarction, or thromboembolism within 12 months 10)Evidence of bleeding diathesis or severe coagulopthy, or patients with those histories 11)Need continuous medication of anticoagulant drug except aspirin 12)Pregnant females or nursing mothers who can not stop lactation after the recruitment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method